NCT00795522View on ClinicalTrials.gov

An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

March 31, 2005

Conditions
Urticaria
Interventions
DRUG

Desloratadine

Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00795522 - An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) | Biotech Hunter | Biotech Hunter